Table 2.
Incidence and characteristics of ICI-related pneumonitis.
| n = 23 | |
|---|---|
| Primary tumor | |
| Lung cancer | 16 |
| Renal cell carcinoma | 4 |
| Malignant melanoma | 2 |
| Gastric cancer | 1 |
| Line of treatment | |
| 1 | 5 |
| 2 | 10 |
| ≥3 | 8 |
| Duration of ICI administration months | |
| 0-59 days | 8 |
| 60-89 days | 3 |
| 90 days or more | 12 |
| Pattern of ICI-related pneumonitis | |
| OP | 11 |
| NSIP | 4 |
| DAD | 5 |
| Other | 3 |
| CTCAE grade of ICI-related pneumonitis | |
| 1 | 3 |
| 2 | 7 |
| 3 | 9 |
| 4 | 1 |
| 5 | 3 |
| Corticosteroid use | |
| Yes | 18 |
| No | 5 |
Abbreviations: CTCAE, Common Terminology Criteria for Adverse Events; DAD, diffuse alveolar damage; ICI, immune checkpoint inhibitor; NSIP, nonspecific interstitial pneumonia; OP, organizing pneumonia.